- Home
- LQDA vs DX Comparison
LQDA vs DX Comparison
Compare LQDA & DX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LQDA
- DX
- Stock Information
- Founded
- LQDA 2004
- DX 1987
- Country
- LQDA United States
- DX United States
- Employees
- LQDA N/A
- DX N/A
- Industry
- LQDA Biotechnology: Pharmaceutical Preparations
- DX Real Estate Investment Trusts
- Sector
- LQDA Health Care
- DX Real Estate
- Exchange
- LQDA Nasdaq
- DX Nasdaq
- Market Cap
- LQDA 1.3B
- DX 1.3B
- IPO Year
- LQDA 2018
- DX N/A
- Fundamental
- Price
- LQDA $13.17
- DX $12.18
- Analyst Decision
- LQDA Strong Buy
- DX Buy
- Analyst Count
- LQDA 9
- DX 4
- Target Price
- LQDA $27.67
- DX $12.50
- AVG Volume (30 Days)
- LQDA 3.0M
- DX 3.5M
- Earning Date
- LQDA 08-06-2025
- DX 07-21-2025
- Dividend Yield
- LQDA N/A
- DX 14.77%
- EPS Growth
- LQDA N/A
- DX N/A
- EPS
- LQDA N/A
- DX 0.79
- Revenue
- LQDA $14,144,000.00
- DX $108,019,000.00
- Revenue This Year
- LQDA $185.38
- DX N/A
- Revenue Next Year
- LQDA $350.95
- DX $22.82
- P/E Ratio
- LQDA N/A
- DX $15.39
- Revenue Growth
- LQDA N/A
- DX N/A
- 52 Week Low
- LQDA $8.26
- DX $10.79
- 52 Week High
- LQDA $19.41
- DX $14.52
- Technical
- Relative Strength Index (RSI)
- LQDA 36.80
- DX 48.64
- Support Level
- LQDA $13.60
- DX $12.04
- Resistance Level
- LQDA $14.63
- DX $12.46
- Average True Range (ATR)
- LQDA 0.96
- DX 0.18
- MACD
- LQDA -0.40
- DX 0.01
- Stochastic Oscillator
- LQDA 0.46
- DX 54.10
About LQDA Liquidia Corporation
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also generates revenue from the sale of Treprostinil Injection through an agreement between its subsidiary and the manufacturer.
About DX Dynex Capital Inc.
Dynex Capital Inc is an internally managed mortgage real estate investment trust, which invests in mortgage-backed securities. The company invests in residential and commercial mortgage-backed securities. Its objective is to provide attractive risk-adjusted returns to shareholders over the long term that are reflective of a leveraged, high quality fixed income portfolio with a focus on capital preservation. Its investments consist principally of Agency mortgage-backed securities including, residential MBS and commercial MBS.